Quest Diagnostics (DGX) Q2 2026 earnings review
Massive Volume Surge Drives Guidance Raise, But Mix Pressures Margins
Quest Diagnostics delivered an impressive 10.2% revenue growth in Q2, fueled by a 13.1% surge in requisition volume. The growth engine is clear: massive hospital collaborations like Corewell Health and Fresenius Medical Care are funneling millions of new tests into Quest's network. However, this volume comes at a cost. The mix shift toward these large, lower-margin contracts caused revenue per requisition to decline 2.8%, and adjusted operating margins compressed by 40 basis points to 16.5%. Despite the margin dilution, the absolute dollar generation is strong enough that management raised full-year 2026 guidance across revenue, EPS, and operating cash flow.
🐂 Bull Case
The strategy to act as a 'lab engine' for major health systems is working. Organic requisition volume jumped 13.0%, proving that partnerships like Corewell and Fresenius can deliver sustained, market-share-grabbing growth.
Management confidently raised FY26 revenue guidance to a midpoint of $12.0B (up from $11.84B) and adjusted EPS to $11.15 (up from $10.73), indicating strong visibility into the second half of the year.
🐻 Bear Case
Revenue grew 10.2%, but adjusted operating income only grew 7.8%. The margin compression (down 40 bps YoY) highlights the margin-dilutive nature of the very hospital contracts driving the top line.
Revenue per requisition reversed its previously stable trend, dropping 2.8% in Q2. As large enterprise contracts make up a larger share of the pie, overall pricing metrics are deteriorating.
⚖️ Verdict: 🟢
Bullish. The margin compression is a known byproduct of onboarding massive hospital deals. Capturing immense volume and executing well enough to raise full-year cash flow and EPS guidance makes this a strong operational quarter.
Key Themes
Strategic Collaborations Delivering Exceptional Volume
Quest's Co-Lab Solutions and joint ventures are the primary engine for top-line growth. The Corewell Health implementation and the Fresenius Medical Care collaboration drove the bulk of the 13.0% organic requisition volume growth. These contracts secure long-term, recurring revenue streams and capture significant market share from hospital outreach programs.
Revenue Per Requisition and Margin Compression
A clear negative contradiction to the volume boom: revenue per requisition is decelerating rapidly, falling 2.8% in Q2. Because the new hospital volume comes at lower unit pricing, adjusted operating margin fell from 16.9% in 25Q2 to 16.5% in 26Q2. Management must prove these deals will scale to higher margins in year two and three as promised.
Advanced Diagnostics Upgrading the Mix
To offset the low-margin hospital volume, Quest is aggressively pushing high-margin advanced diagnostics. The company highlighted double-digit revenue growth in AD-Detect (Alzheimer's) and advanced cardiometabolic/endocrine tests. Securing New York State approval for the Haystack MRD test further bolsters the high-value oncology portfolio.
Operational Excellence & AI Deployment
To protect the bottom line, Quest's 'Invigorate' program is deploying automation inside and outside the lab. Q2 saw the launch of IntelliDraw to guide clinical staff and reduce errors, alongside automated cervical cancer screening processing. These initiatives are critical to achieving the target of 3% annual cost savings.
PAMA and Macro Reimbursement Risks Looming
While 2026 is insulated from PAMA cuts, the structural flaws of the Medicare rate calculation remain. If the 'RESULTS Act' is not passed, Quest faces a potential $100 million headwind in 2027. Combined with the previously flagged 30-40 bps potential hit from ACA disenrollment, macro reimbursement policy remains a structural overhang.
Project Nova Investment Drag
The multi-year 'Project Nova' IT modernization (partnered with Epic) requires significant capital. Management previously guided a $0.25 EPS dilution in 2026, heavily weighted to the second half of the year. Investors must monitor whether this spend remains contained within the $250-$310 million multi-year budget.
Other KPIs
Accelerating significantly from 10.9% in 26Q1 and 8.5% in 25Q4. Organic volume growth was virtually identical at 13.0%, proving that base business and new mega-contracts, rather than M&A, are fueling the expansion.
Stable. Up slightly (1.9%) from $858 million in the prior year. Growth was muted relative to net income (+13.9% YTD) primarily due to a $259M drag from growing accounts receivable, a natural consequence of the massive 10%+ revenue expansion.
Accelerating. Up 27.0% YoY. This reflects ongoing investments in lab automation (Invigorate program), esoteric testing capacity, and the multi-year Project Nova technology overhaul.
Guidance
Accelerating. Implies 8.3% to 9.2% YoY growth. Management confidently raised both the floor and ceiling from the prior guide of $11.78 - $11.90 billion, driven by the flawless onboarding of hospital contracts and sustained advanced diagnostic demand.
Accelerating. Up from the prior range of $10.63 - $10.83. The midpoint ($11.15) implies an impressive ~13% YoY growth over 2025's $9.85. This proves that despite margin percentage compression, the absolute earnings power of the new contracts is highly accretive.
Accelerating. Raised from the prior guide of ~$1.75 billion. Indicates that working capital scaling issues (like the Q2 accounts receivable build) are expected to normalize in the second half of the year.
Key Questions
Margin Trajectory on Mega-Contracts
With revenue per requisition down 2.8% and adjusted operating margins compressing, exactly when do we expect the Corewell and Fresenius contracts to cross over from margin-dilutive to margin-accretive?
Project Nova Spending Cadence
With the guidance raise, has the timeline or cost expectation for Project Nova shifted? How much of the expected H2 margin pressure is driven by this IT investment versus core business mix?
PAMA Data Collection Status
As we approach the critical window for PAMA data reporting, are you seeing the necessary compliance from hospital labs to ensure the 2027 rate adjustments will be based on accurate market data rather than a flawed sample?